Rapid-Infusion Rituximab in Lymphoma Treatment: 2-Year Experience in a Single Institution

Creative Commons License

Atay S., BARIŞTA İ., GÜNDOĞDU F., Akgedik K., Arpaci A.

JOURNAL OF ONCOLOGY PRACTICE, vol.8, no.3, pp.141-143, 2012 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 8 Issue: 3
  • Publication Date: 2012
  • Doi Number: 10.1200/jop.2011.000319
  • Journal Name: JOURNAL OF ONCOLOGY PRACTICE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Emerging Sources Citation Index (ESCI), Scopus
  • Page Numbers: pp.141-143
  • Hacettepe University Affiliated: Yes

Abstract

Purpose: Rituximab is a chimeric anti-CD20 monoclonal antibody. We aimed to explore the safety and tolerability of rapid infusion rituximab, (over 90 minutes) in patients with non-Hodgkin's lymphoma at Hacettepe University Department of Medical Oncology.